NCT00952614View on ClinicalTrials.gov

A Study of a Sustained Release Fluocinolone Implant for Treatment of Central Retinal Vein Occlusion

NACompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

October 31, 2002

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions
Central Retinal Vein Occlusion
Interventions
DEVICE

fluocinolone acetonide (Retisert Implant, Bausch and Lomb)

sustained release device consisting of 0.59 mg of fluocinolone acetonide

Trial Locations (1)

27710

Duke Eye Center, Durham

All Listed Sponsors
collaborator

Bausch & Lomb Incorporated

INDUSTRY

lead

Glenn Jaffe

OTHER

NCT00952614 - A Study of a Sustained Release Fluocinolone Implant for Treatment of Central Retinal Vein Occlusion | Biotech Hunter | Biotech Hunter